MAN1B1 is associated with poor prognosis and modulates proliferation and apoptosis in bladder cancer

Wang, Haifeng; Wu, Jianhui; Gai, Junwei; Yang, Shiqiang; Ma, Qing-Tong; Ma, Hui; Feng, Qiang

doi:10.1016/j.gene.2018.09.022

Cited by 15 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rate of protein synthesis, cellular growth rate (doubling time), protein trafficking time, and the levels of multiple glycan-processing enzymes and nucleotide sugars [68] as well as various protein factors [69]. While the reduced expression of several α1,2-mannosidases catalysing the M9-to-M5 trimming process has been reported in cancer (discussed below) [70][71][72], the possible contribution of these many other cellular and protein factors to the oligomannose-rich glycophenotypes of cancer cells remains unexplored.…”

Section: Pan-cancer Cell Line Glycoprofiling Demonstrates That Oligomannose Is a Cancer-wide Signaturementioning

confidence: 99%

Oligomannosylation and MAN1A1 expression associate strongly with a subset of human cancer types

Chatterjee

Kawahara

Ugonotti

et al. 2021

Preprint

View full text Add to dashboard Cite

Aberrant protein glycosylation is a prominent cancer feature. While many tumour-associated glycoepitopes have been reported, advances in glycoanalytics continue to uncover new associations between glycoproteins and cancer. Guided by a comprehensive literature survey suggesting that oligomannosylation (Man5-9GlcNAc2, M5-M9) is a widespread albeit poorly studied glyco-signature in human cancers, we here re-visit a valuable compilation of nearly 500 LC-MS/MS N-glycomics datasets acquired across 11 human cancer types to systematically test for oligomannose-cancer associations. Firstly, our quantitative glycomics data obtained across 34 cancerous cell lines demonstrated that oligomannosylation, particularly the under-processed M7-M9, is a strong pan-cancer feature. We then showed cell surface expression of oligomannosidic epitopes in the promyelocytic leukemic HL-60 cell line using concanavalin A-based flow cytometry. In keeping with literature, our quantitative glycomics data of tumour and matching control tissues and new MALDI-MS imaging data of tissue microarrays showed a strong cancer-associated elevation of oligomannosylation in both basal cell (p = 1.78 x 10-12) and squamous cell (p = 1.23 x 10-11) skin cancer and colorectal cancer (p = 8.0 x 10-4). The glycomics data also indicated that few cancer types including gastric and liver cancer exhibit unchanged or reduced oligomannose levels, observations also supported by literature and MALDI-MSI. Finally, data from cancer repositories indicated that three α1,2-mannosidases dictate oligomannose expression in cancer cells, and further suggested that deleterious mutations and reduced expression of MAN1A1 are key contributors to the cancer-associated oligomannose elevation. Collectively, these findings open hitherto unexplored avenues for the development of new cancer biomarkers and therapeutic targets.

show abstract

Section: Pan-cancer Cell Line Glycoprofiling Demonstrates That Oligomannose Is a Cancer-wide Signaturementioning

confidence: 99%

Oligomannosylation and MAN1A1 expression associate strongly with a subset of human cancer types

Chatterjee

Kawahara

Ugonotti

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…We examined the influence of CD133+ HPCs on breast cancer cell invasion by Transwell invasion assay [25]. Briefly, the upper and lower chambers of a Transwell insert are separated by polycarbonate microporous membrane (8 μm pore size), which is coated with Matrigel (Thermo Scientific, USA) on the upper chamber surface and dried at room temperature.…”

Section: Transwell Invasion Assaymentioning

confidence: 99%

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

et al. 2020

View full text Add to dashboard Cite

Background Human CD133+ hematopoietic progenitor cells (HPCs) are a specific subset of cells that can regulate tumor malignancy. However, the mechanism by which CD133+ HPCs affect the malignancy of human breast cancer has not been reported. Methods CD133+ HPCs were isolated and purified from human umbilical cord blood (UCB). We used in vitro culture of MCF-7 and MDA-MB-231 cell lines, and MCF-7 and MDA-MB-231 cells in nude mice to evaluate whether CD133+ HPCs affected the apoptosis, proliferation, invasion and epithelial mesenchymal transition EMT of breast cancer cells. Results Co-culture with CD133+ HPCs, but not UCB CD133- cells, promoted the proliferation of human breast cancer MCF-7 and MDA-MB-231 cells, accompanied by reducing in vitro spontaneous apoptosis. Co-administration of these two lines with CD133+ HPCs significantly enhanced the growth of implanted breast cancer in vivo. Furthermore, co-culture with CD133+ HPCs, enhanced the invasion of breast cancer cells, N-cadherin and Vimentin expression, but reduced E-cadherin expression in breast cancer cells. Conclusions Our study demonstrated that CD133+ HPCs enhance the malignancy of breast cancer cells by attenuating spontaneous apoptosis and promoting the process of epithelial mesenchymal transition. These findings may provide new insights into the role of human CD133+ HPCs in breast cancer pathogenesis. Therefore, CD133+ HPCs may be a new therapeutic target for inhibiting the progression of breast cancer.

show abstract

“…We tested the role of CD133 + HPCs in spontaneous apoptosis of MCF-7 or MDA-MB-231 cells by flow cytometry [22].The cancer cells were cultured alone (blank control), or together with CD133 + HPCs or CD133-HUCBCs at 20:1 were cultured in the upper and lower chambers of Transwell chamber (0.4 µm pore size), respectively, for 72 h. The cancer cells (3 × 10 5 cells/tube) were tested for their apoptosis by flow cytometry after staining with Annexin V-FITC and Propidium iodide (PI, MyBioSource). The apoptotic FITC + and FITC + PI + cells were quantified.…”

Section: Cell Apoptosis Assaymentioning

confidence: 99%

Human CD133-Positive Hematopoietic Progenitor Cells Enhance the Malignancy of Breast Cancer Cells

Zhang

Qinglian

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Human CD133 + hematopoietic progenitor cells (HPCs) are a specific subset of cells and can regulate the malignancy of tumors. However, how CD133 + HPCs affect the malignancy of human breast cancer has not been clarified.Methods: The CD133 + HPCs were isolated and purified from human umbilical cord blood (UCB) .We used in vitro culture of the MCF-7 and MDA-MB-231 cell line, and MCF-7 and MDA-MB-231 cells into nude mice in order to tested whether CD133 + HPCs affected the apoptosis, proliferation, invasion and EMT of breast cancer cells.Results: Co-culture with CD133 + HPCs, but not UCB CD133- cells, promoted the proliferation of human breast cancer MCF-7 or MDA-MB-231 cells, accompanied by reducing their spontaneous apoptosis in vitro and co-administration with CD133 + HPCs significantly enhanced the growth of implanted breast cancer in vivo. Furthermore, co-culture with CD133 + HPCs, enhanced the invasion of breast cancer cells, N-cadherin and Vimentin expression, but reduced E-cadherin expression in Breast cancer cells.Conclusions: The data indicated that CD133 + HPCs enhanced the malignancy of breast cancer cells by inhibiting their spontaneous apoptosis and promoting the process of epithelial mesenchymal transition. These findings may provide new insights in the role of human CD133 + HPCs in the pathogenic process of breast cancer. Therefore, CD133 + HPCs may be a new therapeutic target for inhibiting the progression of breast cancer.

show abstract

MAN1B1 is associated with poor prognosis and modulates proliferation and apoptosis in bladder cancer

Cited by 15 publications

References 22 publications

Oligomannosylation and MAN1A1 expression associate strongly with a subset of human cancer types

Oligomannosylation and MAN1A1 expression associate strongly with a subset of human cancer types

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

Human CD133-Positive Hematopoietic Progenitor Cells Enhance the Malignancy of Breast Cancer Cells

Contact Info

Product

Resources

About